An integrative genomic approach in oesophageal cells identifies TRB3 as a bile acid responsive gene, downregulated in Barrett's oesophagus, which regulates NF-kappaB activation and cytokine levels.
Reflux of gastroduodenal contents and consequent inflammatory responses are associated with the development of Barrett's oesophagus (BO) and the promotion of oesophageal adenocarcinoma (OAC). Deregulation of inflammatory processes is a hallmark of oesophageal cancer. In this study, we aimed to investigate (i) the transcriptional responses to deoxycholic acid (DCA) in cell lines representative of either end of the oesophageal cancer sequence, (ii) the expression of DCA-regulated genes in data charting oesophageal carcinogenesis and (iii) the impact of these genes on oesophageal inflammatory signalling. Gene expression microarrays were utilized to demonstrate differential transcriptional responses between squamous (HET-1A) and adenomatous (SKGT4) cell lines exposed to DCA. Differential basal and DCA-inducible expression of cytokines such as interleukin (IL) 8 was observed between both cell types. A cohort of DCA-regulated genes specific to each cell type was identified in microarray experimentation and subsequently validated. Cell type-specific genes included TRB3, CXCL14, GDF15 and LIF in HET-1A cells, with COX2-, ESM1-, URHF1- and IL1alpha-and IL1beta-specific expression in SKGT4 cells. Over 30% of the genes altered in BO and OAC were shown to be regulated by DCA utilizing an integrative genomic approach. One such gene, tribbles-homology-3 (TRB3) was induced specifically in HET-1A cells, absent in SKGT4 cells and decreased in BO samples in silico and in vivo. Inhibition and re-introduction of TRB3 in HET-1A and SKGT4 cells, respectively, demonstrated the ability of TRB3 to regulate inflammatory signalling through nuclear factor-kappaB. This study identifies mechanisms through which bile acids such as DCA, in conjunction with the loss of key signalling molecules, could regulate oesophageal metaplasticity.
Department of Clinical Medicine and Institute of Molecular Medicine, Trinity College Dublin, Dublin 2, Ireland. shduggan@tcd.ie
Shane P
SP
Duggan
Fiona M
FM
Behan
Murat
M
Kirca
Sinead
S
Smith
John V
JV
Reynolds
Aideen
A
Long
Dermot
D
Kelleher
D001471:Barrett Esophagus / Q000209:etiology* / Q000235:genetics / Q000473:pathology; D018797:Cell Cycle Proteins / Q000235:genetics* / Q000502:physiology; D045744:Cell Line, Tumor; D003840:Deoxycholic Acid / Q000494:pharmacology*; D015536:Down-Regulation; D004947:Esophagus / Q000378:metabolism / Q000473:pathology*; D020869:Gene Expression Profiling; D005786:Gene Expression Regulation / Q000187:drug effects; D023281:Genomics; D006801:Humans; D016209:Interleukin-8 / Q000032:analysis*; D016328:NF-kappa B / Q000378:metabolism*; D017346:Protein Serine-Threonine Kinases / Q000235:genetics* / Q000502:physiology / Q000037:antagonists & inhibitors; D012097:Repressor Proteins / Q000235:genetics* / Q000502:physiology; D020218:Response Elements / Q000502:physiology*; D015398:Signal Transduction
D018797:Cell Cycle Proteins; D016209:Interleukin-8; D016328:NF-kappa B; D012097:Repressor Proteins; C474831:TRIB3 protein, human; D003840:Deoxycholic Acid; D017346:Protein Serine-Threonine Kinases